{"id":64023,"date":"2026-04-27T14:26:40","date_gmt":"2026-04-27T06:26:40","guid":{"rendered":"https:\/\/flcube.com\/?p=64023"},"modified":"2026-04-27T14:26:41","modified_gmt":"2026-04-27T06:26:41","slug":"china-resources-double-crane-to-acquire-nanjing-xinbai-pharma-from-boya-biological-for-rmb-235-5-million-expanding-injectables-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64023","title":{"rendered":"China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio"},"content":{"rendered":"\n<p><strong>Boya Biological Pharmacy Co., Ltd.<\/strong>, (<a href=\"https:\/\/www.google.com\/finance\/quote\/300294:SHE\">SHE: 300294<\/a>) a China-based pharmaceutical company, has agreed to divest <strong>100% equity<\/strong> of <strong>Nanjing Xinbai Pharmaceutical Co., Ltd.<\/strong> to <strong>China Resources Double-Crane Pharmaceutical Co., Ltd.<\/strong> (CR Double-Crane) for <strong>RMB 235.5 million<\/strong> (approximately <strong>USD 34.4 million<\/strong>).<\/p>\n\n\n\n<p>The transaction marks a strategic portfolio realignment for Boya Biological and bolsters CR Double-Crane\u2019s position in the <strong>hospital-focused injectables segment<\/strong>, particularly in <strong>lyophilized powder injections<\/strong> and <strong>small-volume parenterals<\/strong>\u2014key dosage forms in China\u2019s acute care settings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Seller<\/strong><\/td><td>Boya Biological Pharmacy Co., Ltd. (China)<\/td><\/tr><tr><td><strong>Buyer<\/strong><\/td><td>China Resources Double-Crane Pharmaceutical Co., Ltd. (State-owned enterprise under China Resources Group)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Nanjing Xinbai Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td>RMB 235.5 million (~USD 34.4 million)<\/td><\/tr><tr><td><strong>Equity Stake<\/strong><\/td><td>100%<\/td><\/tr><tr><td><strong>Core Assets<\/strong><\/td><td>Manufacturing facilities for lyophilized powders, small-volume injections, and oral solid dosage forms<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>All products compliant with China GMP standards<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-portfolio-fit\">Strategic Rationale &amp; Portfolio Fit<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For CR Double-Crane<\/strong>: Strengthens its <strong>hospital drug franchise<\/strong>, which accounts for >65% of its revenue. Xinbai\u2019s sterile injectables align with national priorities for high-quality generic parenterals.<\/li>\n\n\n\n<li><strong>For Boya Biological<\/strong>: Streamlines operations by exiting non-core manufacturing assets to focus on biologics and specialty APIs.<\/li>\n\n\n\n<li><strong>Market Position<\/strong>: Xinbai\u2019s product portfolio serves Tier II\/III hospitals across Jiangsu, Anhui, and Shandong provinces, complementing CR Double-Crane\u2019s nationwide distribution network.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-operational-context\">Financial &amp; Operational Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Valuation Multiple<\/strong>: Implied EV\/revenue multiple estimated at <strong>~1.8x<\/strong>, reflecting modest margins typical of mature generic injectable producers.<\/li>\n\n\n\n<li><strong>Integration Plan<\/strong>: Production lines to be retained; commercial operations migrated to CR Double-Crane\u2019s sales force by Q1 2027.<\/li>\n\n\n\n<li><strong>Synergies<\/strong>: Expected cost savings of <strong>RMB 20\u201330 million annually<\/strong> through procurement consolidation and logistics optimization.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-backdrop\">Industry Backdrop<\/h2>\n\n\n\n<p>China\u2019s <strong>generic injectables market<\/strong> remains under consolidation pressure as regulators enforce stringent quality standards and volume-based procurement (VBP) policies drive pricing discipline. State-owned enterprises like CR Double-Crane are actively acquiring compliant manufacturers to secure supply chain resilience and expand formulary breadth.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief summarizes a disclosed transaction. Closing is subject to customary regulatory approvals and may be influenced by China\u2019s evolving pharmaceutical industrial policy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u535a\u96c5\u751f\u7269\uff1a\u516c\u53f8\u5173\u4e8e\u8f6c\u8ba9\u5357\u4eac\u65b0\u767e\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8100\u80a1\u6743\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u535a\u96c5\u751f\u7269\uff1a\u516c\u53f8\u5173\u4e8e\u8f6c\u8ba9\u5357\u4eac\u65b0\u767e\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8100%\u80a1\u6743\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-2e5b4900-7ac1-45f5-aa3e-cfed6a3fba85\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u535a\u96c5\u751f\u7269\uff1a\u516c\u53f8\u5173\u4e8e\u8f6c\u8ba9\u5357\u4eac\u65b0\u767e\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8100\u80a1\u6743\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\">\u535a\u96c5\u751f\u7269\uff1a\u516c\u53f8\u5173\u4e8e\u8f6c\u8ba9\u5357\u4eac\u65b0\u767e\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8100%\u80a1\u6743\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u535a\u96c5\u751f\u7269\uff1a\u516c\u53f8\u5173\u4e8e\u8f6c\u8ba9\u5357\u4eac\u65b0\u767e\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8100\u80a1\u6743\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2e5b4900-7ac1-45f5-aa3e-cfed6a3fba85\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2238,511,1247,4714],"class_list":["post-64023","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-china-resources-double-crane-pharmaceutical","tag-cr-boya-biological-pharmacy","tag-she-300294","tag-xinbai-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest 100% equity of Nanjing Xinbai Pharmaceutical Co., Ltd. to China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane) for RMB 235.5 million (approximately USD 34.4 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64023\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio\" \/>\n<meta property=\"og:description\" content=\"Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest 100% equity of Nanjing Xinbai Pharmaceutical Co., Ltd. to China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane) for RMB 235.5 million (approximately USD 34.4 million).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64023\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T06:26:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-27T06:26:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64023#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64023\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio\",\"datePublished\":\"2026-04-27T06:26:40+00:00\",\"dateModified\":\"2026-04-27T06:26:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64023\"},\"wordCount\":354,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Resources Double-Crane Pharmaceutical\",\"CR Boya Biological Pharmacy\",\"SHE: 300294\",\"Xinbai Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64023#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64023\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64023\",\"name\":\"China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-27T06:26:40+00:00\",\"dateModified\":\"2026-04-27T06:26:41+00:00\",\"description\":\"Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest 100% equity of Nanjing Xinbai Pharmaceutical Co., Ltd. to China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane) for RMB 235.5 million (approximately USD 34.4 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64023#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64023\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64023#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest 100% equity of Nanjing Xinbai Pharmaceutical Co., Ltd. to China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane) for RMB 235.5 million (approximately USD 34.4 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64023","og_locale":"en_US","og_type":"article","og_title":"China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio","og_description":"Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest 100% equity of Nanjing Xinbai Pharmaceutical Co., Ltd. to China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane) for RMB 235.5 million (approximately USD 34.4 million).","og_url":"https:\/\/flcube.com\/?p=64023","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-27T06:26:40+00:00","article_modified_time":"2026-04-27T06:26:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64023#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64023"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio","datePublished":"2026-04-27T06:26:40+00:00","dateModified":"2026-04-27T06:26:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64023"},"wordCount":354,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Resources Double-Crane Pharmaceutical","CR Boya Biological Pharmacy","SHE: 300294","Xinbai Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64023#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64023","url":"https:\/\/flcube.com\/?p=64023","name":"China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-27T06:26:40+00:00","dateModified":"2026-04-27T06:26:41+00:00","description":"Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest 100% equity of Nanjing Xinbai Pharmaceutical Co., Ltd. to China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane) for RMB 235.5 million (approximately USD 34.4 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64023#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64023"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64023#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64023"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64023\/revisions"}],"predecessor-version":[{"id":64026,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64023\/revisions\/64026"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64023"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64023"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}